Expertise in
17
conditions

Xiaoping P. Zou

321 Zhongshan Road, 
Nanjing, CN 
Expertise in
17
conditions
321 Zhongshan Road, 
Nanjing, CN 

Overview

Xiaoping Zou practices practicing medicine in Nanjing, China.

Zou is highly rated in 17 conditions, according to our data. Their clinical expertise encompasses Stomach Cancer, Hepatic Venoocclusive Disease with Immunodeficiency, Pancreatic Cancer, Endoscopy, and Gastrectomy.

They are actively involved in clinical research, co-authoring 272 peer reviewed articles and participating in 5 clinical trials.

Locations

321 Zhongshan Road, Nanjing, 210008, China
Other Locations
No. 321, Zhongshan Road, Nanjing, 210008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: Hemay007
Study Phase: Phase 2
Evaluation of the Simplified Diagnosis Tool for Chinese IBS-C (Irritable Bowel Syndrome With Constipation) Patients
Evaluation of the Simplified Diagnosis Tool for Chinese IBS-C (Irritable Bowel Syndrome With Constipation) Patients
Enrollment Status: Completed
Publish Date: December 28, 2023
View 4 Less Clinical Trials

272 Total Publications

Erratum: [Corrigendum] FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells.
Erratum: [Corrigendum] FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells.
Journal: Oncology letters
Published: August 01, 2026

Frequently Asked Questions about Xiaoping P. Zou

Is Xiaoping P. Zou a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Xiaoping P. Zou is classified as an Distinguished expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xiaoping P. Zou participate in research or clinical trials?

Yes. Xiaoping P. Zou has published 272 articles and abstracts on conditions like Stomach Cancer. You can view a list of Xiaoping P. Zou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zou's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile